Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO Italy 2020 | Italian perspective: managing DLBCL

Gerardo Musuraca • 17 Sep 2020
SOHO Italy 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T R-CHOP

Gerardo Musuraca, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, outlines the Italian perspective of the diagnosis, treatment, and management of diffuse large B-cell lymphoma (DLBCL) including understanding molecular alterations involved in the pathogenesis of disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Gerardo Musuraca

The management of DLBCL and the importance of characterizing molecular subtypes
2:29
The management of DLBCL and the importance of characterizing molecular subtypes
Gerardo Musuraca • 24 Oct 2022
Exciting advances in DLBCL: molecular characterization of subtypes & novel immunotherapeutic agents
1:12
Exciting advances in DLBCL: molecular characterization of subtypes & novel immunotherapeutic agents
Gerardo Musuraca • 24 Oct 2022
Evolving treatment landscape of DLBCL
2:34
Evolving treatment landscape of DLBCL
Gerardo Musuraca • 17 Sep 2020

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals